Editorial: MTTP, hepatic steatosis and plasma lipids – still more questions than answers (Englisch)
- Neue Suche nach: Chen, Vincent L.
- Neue Suche nach: Chen, Vincent L.
In:
Alimentary Pharmacology & Therapeutics
;
58
, 3
;
368-369
;
2023
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Editorial: MTTP, hepatic steatosis and plasma lipids – still more questions than answers
-
Beteiligte:Chen, Vincent L. ( Autor:in )
-
Erschienen in:Alimentary Pharmacology & Therapeutics ; 58, 3 ; 368-369
-
Verlag:
-
Erscheinungsdatum:01.08.2023
-
Format / Umfang:2 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Datenquelle:
Inhaltsverzeichnis – Band 58, Ausgabe 3
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 265
-
Issue Information| 2023
- 268
-
Systematic review and meta‐analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitisAlphonsus, Lotus / De Silva, Theshani A. / Ma, Christopher / MacDonald, John K. / Hanzel, Jurij / Beaton, Melanie / Bessissow, Talat / Kayal, Maia / Sedano, Rocio / Singh, Siddharth et al. | 2023
- 283
-
A randomised, double‐blind, placebo‐controlled study of the LAG‐3‐depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitisD'Haens, Geert / Peyrin‐Biroulet, Laurent / Marks, Daniel J. B. / Lisi, Edoardo / Liefaard, Lia / Beaton, Andrew / Srinivasan, Naren / Bouma, Gerben / Prasad, Naveen / Cameron, Raymond et al. | 2023
- 297
-
Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort studyKochhar, Gursimran S. / Desai, Aakash / Farraye, Francis A. / Cross, Raymond K. / El‐Hachem, Sandra / Dulai, Parambir S. / Regueiro, Miguel et al. | 2023
- 309
-
Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point‐of‐care measurements of skeletal muscle mass in patients with inflammatory bowel diseaseNguyen, Anke L. / Burns, Megan / Herath, Madhuni / Lambell, Kate / Holt, Darcy / Fitzpatrick, Jessica / Milat, Frances / Ebeling, Peter R. / Gibson, Peter R. / Moore, Gregory T. et al. | 2023
- 322
-
Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLDLee, Yun Kyu / Koo, Bo Kyung / Joo, Sae Kyung / Lee, Dong Hyeon / Jang, Heejoon / Chai, Jee Won / Lee, Myoung Seok / Jang, Si Won / So, Young Ho / Park, Jeong Hwan et al. | 2023
- 334
-
Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis BChen, Chien‐Hung / Peng, Cheng‐Yuan / Hu, Tsung‐Hui / Wang, Jing‐Houng / Hung, Chao‐Hung / Lu, Sheng‐Nan et al. | 2023
- 346
-
Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinomaAllaire, Manon / Campion, Bertille / Demory, Alix / Larrey, Edouard / Wagner, Mathilde / Rudler, Marika / Roux, Charles / Blaise, Lorraine / Carrie, Nathalie G. / Thabut, Dominique et al. | 2023
- 357
-
Editorial: Increased risk of cervical dysplasia with immunomodulator use in IBDKane, Sunanda et al. | 2023
- 359
-
Editorial: LAG‐3‐depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?Lobatón, Triana / Truyens, Marie et al. | 2023
- 361
-
Editorial: Pip pip to PIP's (post‐inflammatory polyps) as a neoplasia risk factor in IBD?Velayos, Fernando S. et al. | 2023
- 363
-
Editorial: Pip pip to PIPs (post‐ inflammatory polyps) as a neoplasia risk factor in IBD? Authors' replyKirchgesner, Julien / Beaugerie, Laurent et al. | 2023
- 364
-
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD?Pappa, Angeliki / Wenzl, Tobias et al. | 2023
- 366
-
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' replyHuang, Daniel Q. / Loomba, Rohit et al. | 2023
- 368
-
Editorial: MTTP, hepatic steatosis and plasma lipids – still more questions than answersChen, Vincent L. et al. | 2023
- 370
-
Editorial: MTTP, hepatic steatosis, and plasma lipids—still more questions than answers. Authors' replyHehl, Leonida / Schneider, Carolin Victoria / Rader, Daniel J. et al. | 2023
- 372
-
Editorial: Let your muscles do the talking—what can muscle quality tell us about hepatic fibrosis?Petroff, David / Wiegand, Johannes / Karlas, Thomas et al. | 2023
- 374
-
Editorial: Let your muscles do the talking—what can muscle quality tell us about hepatic fibrosis? Authors' replyLee, Yun Kyu / Koo, Bo Kyung / Kim, Won et al. | 2023
- 376
-
Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel diseaseTassone, Daniel / Hartley, Imogen / Ding, Nik Sheng et al. | 2023
- 378
-
Letter: Should metabolically healthy NAFLD also be included in the diagnostic criteria for metabolic syndrome?Lu, Linjie / Wen, Yu / Zhai, Haoliang / Shen, Hong et al. | 2023